Coluracetam (INN) (code name BCI-540; formerly MKC-231) is a nootropic agent of the racetam family. It was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer's disease. After the drug failed to reach endpoints in its clinical trials it was in-licensed by BrainCells Inc for investigations into major depressive disorder (MDD), which was preceded by being awarded a "Qualifying Therapeutic Discovery Program Grant" by the state of California. Findings from phase IIa clinical trials have suggested that it would be a potential medication for comorbid MDD with generalized anxiety disorder (GAD). BrainCells Inc is currently[when?] out-licensing the drug for this purpose. [full citation needed] It may also have potential use in prevention and treatment of ischemic retinopathy and retinal and optic nerve injury.
Product Description
Coluracetam 135463-81-9
Product Name: Coluracetam MKC-231
Chemical Name: N-(2,3-Dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide
CAS No.: 135463-81-9
Formula: C19H23N3O3
Purity:99%
Molecular Weight:341.40
Appearance:white crystal powder
Boiling Point:634.1°C at 760 mmHg °C
Description: Coluracetam (BCI-540) is a nootropic drug of the racetam family
Application:mainly applied to promote intellectual product. /raw material used in Synthesis/ pharmaceutical raw material and for research
Specification:
Name: Coluracetam
CAS: 135463-81-9
Purity:99
| Chemical name | Coluracetam |
| CAS No. | 135463-81-9 |
| Synonym | Coluracetam |
| Molecular Formula | C19H23N3O3 |
| Other name | MKC-231 |
| Store at | Room temperature |
| Purity | 99% min |
| Appearance | White to off white powder |
Main Function:
· Improved Memory
· Increased Learning Ability
· Improved Cognitive Processing
· Heightened Reflexes
· Heightened Perception
· Reduced Anxiety
· Reduced Depression
没有评论:
发表评论